- Home
- AUPH vs IART Comparison
AUPH vs IART Comparison
Compare AUPH & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- IART
- Stock Information
- Founded
- AUPH 1993
- IART 1989
- Country
- AUPH Canada
- IART United States
- Employees
- AUPH N/A
- IART N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- IART Medical/Dental Instruments
- Sector
- AUPH Health Care
- IART Health Care
- Exchange
- AUPH Nasdaq
- IART Nasdaq
- Market Cap
- AUPH 1.4B
- IART 1.2B
- IPO Year
- AUPH 1999
- IART 1995
- Fundamental
- Price
- AUPH $11.47
- IART $14.81
- Analyst Decision
- AUPH Strong Buy
- IART Hold
- Analyst Count
- AUPH 2
- IART 6
- Target Price
- AUPH $13.00
- IART $16.20
- AVG Volume (30 Days)
- AUPH 1.9M
- IART 1.1M
- Earning Date
- AUPH 11-06-2025
- IART 11-03-2025
- Dividend Yield
- AUPH N/A
- IART N/A
- EPS Growth
- AUPH N/A
- IART N/A
- EPS
- AUPH 0.42
- IART N/A
- Revenue
- AUPH $260,111,000.00
- IART $1,621,738,000.00
- Revenue This Year
- AUPH $17.33
- IART $5.74
- Revenue Next Year
- AUPH $14.31
- IART $4.35
- P/E Ratio
- AUPH $27.48
- IART N/A
- Revenue Growth
- AUPH 25.59
- IART 3.53
- 52 Week Low
- AUPH $6.55
- IART $11.06
- 52 Week High
- AUPH $13.54
- IART $27.13
- Technical
- Relative Strength Index (RSI)
- AUPH 47.42
- IART 51.77
- Support Level
- AUPH $11.08
- IART $14.18
- Resistance Level
- AUPH $11.87
- IART $14.96
- Average True Range (ATR)
- AUPH 0.62
- IART 0.71
- MACD
- AUPH -0.14
- IART -0.01
- Stochastic Oscillator
- AUPH 44.06
- IART 63.24
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.